Status:
COMPLETED
Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation
Lead Sponsor:
University Hospital, Brest
Conditions:
Rheumatoid Arthritis
COVID
Eligibility:
All Genders
18+ years
Brief Summary
The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, th...
Eligibility Criteria
Inclusion
- Rheumatoid arthritis satisfying ACR/EULAR criteria
- Ongoing DMARD therapy
Exclusion
- Inhability to consent
Key Trial Info
Start Date :
April 23 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 23 2020
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04393233
Start Date
April 23 2020
End Date
August 23 2020
Last Update
August 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU de Brest
Brest, France, 29609